Recent blog posts
Chronic hand eczema Indication Strategy Report 2026: IL-4Rα, Trials and Deals
Latest Hotspot
8 min read
Chronic hand eczema Indication Strategy Report 2026: IL-4Rα, Trials and Deals
21 July 2026
Chronic hand eczema indication strategy report covering epidemiology, IL-4Rα biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Prurigo nodularis Indication Strategy Report 2026: IL-31RA, Trials and Deals
Latest Hotspot
8 min read
Prurigo nodularis Indication Strategy Report 2026: IL-31RA, Trials and Deals
21 July 2026
Prurigo nodularis indication strategy report covering epidemiology, IL-31RA biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Sarcoidosis Indication Strategy Report 2026: TNF, Trials and Deals
Latest Hotspot
8 min read
Sarcoidosis Indication Strategy Report 2026: TNF, Trials and Deals
21 July 2026
Sarcoidosis indication strategy report covering epidemiology, TNF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
IgG4-related disease Indication Strategy Report 2026: CD19, Trials and Deals
Latest Hotspot
8 min read
IgG4-related disease Indication Strategy Report 2026: CD19, Trials and Deals
21 July 2026
IgG4-related disease indication strategy report covering epidemiology, CD19 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Takayasu arteritis Indication Strategy Report 2026: IL-6R, Trials and Deals
Latest Hotspot
8 min read
Takayasu arteritis Indication Strategy Report 2026: IL-6R, Trials and Deals
21 July 2026
Takayasu arteritis indication strategy report covering epidemiology, IL-6R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Antiphospholipid syndrome Indication Strategy Report 2026: C5, Trials and Deals
Latest Hotspot
8 min read
Antiphospholipid syndrome Indication Strategy Report 2026: C5, Trials and Deals
21 July 2026
Antiphospholipid syndrome indication strategy report covering epidemiology, C5 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Relapsing polychondritis Indication Strategy Report 2026: IL-6R, Trials and Whitespace
Latest Hotspot
8 min read
Relapsing polychondritis Indication Strategy Report 2026: IL-6R, Trials and Whitespace
21 July 2026
Relapsing polychondritis indication strategy report covering epidemiology, IL-6R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Behcet disease Indication Strategy Report 2026: TNF, Trials and Deals
Latest Hotspot
8 min read
Behcet disease Indication Strategy Report 2026: TNF, Trials and Deals
21 July 2026
Behcet disease indication strategy report covering epidemiology, TNF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
VEXAS syndrome Indication Strategy Report 2026: UBA1, Trials and Deals
Latest Hotspot
8 min read
VEXAS syndrome Indication Strategy Report 2026: UBA1, Trials and Deals
21 July 2026
VEXAS syndrome indication strategy report covering epidemiology, UBA1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Cryopyrin-associated periodic syndromes Indication Strategy Report 2026: NLRP3, Trials and Deals
Latest Hotspot
8 min read
Cryopyrin-associated periodic syndromes Indication Strategy Report 2026: NLRP3, Trials and Deals
21 July 2026
Cryopyrin-associated periodic syndromes indication strategy report covering epidemiology, NLRP3 biology, active trials, competition and deal signals using...
Read →
Familial Mediterranean fever Indication Strategy Report 2026: MEFV, Trials and Deals
Latest Hotspot
8 min read
Familial Mediterranean fever Indication Strategy Report 2026: MEFV, Trials and Deals
21 July 2026
Familial Mediterranean fever indication strategy report covering epidemiology, MEFV biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Adult-onset Still disease Indication Strategy Report 2026: IL-1β, Trials and Deals
Latest Hotspot
8 min read
Adult-onset Still disease Indication Strategy Report 2026: IL-1β, Trials and Deals
21 July 2026
Adult-onset Still disease indication strategy report covering epidemiology, IL-1β biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →